Ping Yan

Prognostic values of human epididymis protein 4 expression in patients with endometrial cancer: A systematic review and meta‐analysis

AbstractBackgroundThere is no consensus on the correlation between human epididymis protein 4 (HE4) and prognosis of endometrial cancer (EC). Therefore, we performed a meta‐analysis to assess the relationship between HE4 and prognosis of EC.MethodsIn this systematic review and meta‐analysis, the databases were searched. Correlation of serum or tissue HE4 with clinicopathological characteristics was determined by odds ratio (OR) or standardized mean difference (SMD) with 95% confidence interval (CI), respectively. The hazard ratio (HR) with 95% CI was calculated to evaluate the correlation between HE4 and survival outcome.ResultsA total of 38 published studies were eligible. We found that high levels of serum HE4 were associated with FIGO III‐IV stage (SMD = 1.58, 95%CI: 1.18–1.98, p < 0.001), grade 3 (SMD = 0.66, 95%CI: 0.39–0.93, p = 0.001), ≥50% myometrial invasion (SMD = 0.78, 95%CI: 0.58–0.99, p < 0.001), lymphovascular space invasion (SMD = 0.82, 95%CI: 0.54–1.11, p = 0.001), lymph node metastasis (SMD = 1.27, 95%CI: 0.84–1.69, p < 0.001), cervical involvement (SMD = 0.71, 95%CI: 0.43–0.98, p = 0.003), parametrial involvement (SMD = 1.03, 95%CI: 0.71–1.35, p < 0.001) and peritoneal cytology (SMD = 0.49, 95%CI: 0.22–0.75, p < 0.001). High expression of tissue HE4 was only significantly associated with lymph node metastasis (OR = 6.19, 95%CI: 2.07–18.50, p = 0.001). High levels of serum HE4 were significantly associated with poor overall survival (univariate: HR = 3.77, 95%CI: 1.94–7.32, p < 0.001; multivariate: HR = 2.15, 95%CI: 1.65–2.80, p < 0.001) and disease‐free survival (univariate: HR = 2.89, 95%CI: 2.14–3.88, p < 0.001; multivariate: HR = 2.31, 95%CI:1.20–2.67, p < 0.001) in EC. Compared with cancer antigen 125, serum HE4 may be a better prognostic indicator for EC.ConclusionsHigh HE4 expression is associated with poor prognosis of EC and may be a potential prognostic biomarker for EC.

miR-214-5p increases the radiosensitivity of cervical cancer by targeting ROCK1 expression

The tolerance of cervical cancer to radiotherapy is a major factor affecting treatment outcomes. The miR-214-5p is involved in the regulation of biological processes such as tumor proliferation and metastasis. The aim of the study was to explore the role of miR-214-5p and Rho-associated coiled-coil containing protein kinase 1 (ROCK1) in cervical cancer and their response to radiotherapy in cervical cancer patients. Fifty-three cervical cancer tissue samples were collected to analyze the level of miR-214-5p in patients with different responses to radiotherapy. Cervical cancer cell lines with radiation resistance were selected to explore the role of miR-214-5p in radiosensitivity. The wound healing, transwell migration, clone formation assay, and in vivo analysis were utilized to evaluate the effect of miR-214-5p on the radiation sensitivity of cervical cancer cells. Patients with poor radiotherapy responses demonstrated low levels of miR-214-5p. The upregulation of miR-214-5p decreased migration and invasion ability of radiotherapy-resistant cells. The bioinformatic analysis showed that ROCK1 is a candidate target gene of miR-214-5p, and this was confirmed with dual luciferase reporter assay showing that miR-214-5p directly interacts with the 3'untranslated region (3'UTR) of ROCK1. Decreased ROCK1 improved the radiosensitivity of cervical cancer in vitro and in vivo, and the overexpression of ROCK1 decreased the radiosensitivity effect of miR-214-5p in cervical cancer cells. The miR-214-5p can regulate the radiation sensitivity of cervical cancer cells by targeting the mRNA of ROCK1 and regulating its expression.